We report the first case of recently characterized species M.
Introduction
Continued improvement of techniques for identification of mycobacteria has produced a resurgence of interest in diseases caused by species other than Mycobacterium tuberculosis. Currently there are more than 150 species of nontuberculous mycobacteria, and more than half are considered definite or potential pathogens in humans [1] .
Mycobacterium monacense is rapidly growing nontuberculous mycobacteria, first described in 2006 by Reischl et al. [2] . The name monacense come from Monacum, the Latin name of the German city of Munich, where the first strain was isolated. Subsequently five additional reports [3] [4] [5] [6] [7] have been published that describe infection by this new species. Here we report the first case of M. monacense associated with chronic nodular vasculitis infecting a woman in Ecuador.
Erythema induratum was previously described in association with tuberculosis in the middle of the 19th century. The clinical picture is characterized by tender violaceous nodules and plaques most commonly affecting the posterior lower legs (usually calves), with the shins involved less often. The nodules are tender and erythematous (those may ulcerate with bluish borders), and cold weather may be a precipitating factor. About half of the patients have a past or present history of tuberculosis. This is most often pulmonary tuberculosis, with cervical lymphadenopathy second. Erythema induratum often remains undiagnosed or misdiagnosed because it is often mistaken for other types of chronic nodules of the lower extremities.
Case Report
A 29-year-old woman with a previous clinical diagnosis of erythema nodosum 4 months before was admitted to hospital with chronic recurrent nodular lesions in both legs associated with moderate pain and erythema. She had previously received topical steroid injections in the lesions, with partial improvement. Four days before admission, she noted a new nodular lesion on the anterior aspect of her left knee.
The skin lesions were tender erythematous nodules approximately 3 cm in diameter located on the anterior and posterior aspects both legs (Fig. 1 ). An ulcerated nodule with an abscess was present on the medial aspect of her left knee. At admission, here complete blood count was 8580 leucocytes with 50.8% neutrophils, hemoglobin 12.4 g/dL and C-reactive protein 68.99 mg/dL. Because of the possibility of erythema induratum, a chest X-ray was conducted, which revealed no pathologic lesions on the lungs. Serology for hepatitis B and C virus was negative.
A deep biopsy of the nodular lesion was performed; the biopsy sample was sent for histopathologic, bacteriologic and mycobacteriologic diagnosis. Results revealed lobular panniculitis consistent with nodular vasculitis (Fig. 1 ). ZiehlNeelsen staining, performed on a direct biopsy sample, was negative for acid-fast bacilli.
The biopsy sample was cultured on chocolate agar, blood agar, MacConkey agar, Lowenstein-Jensen media and Mycobacteria Growth Indicator Tube (MGIT). After 5 days' growth in MGIT and after 7 days evidence of growth was observed on agar plates as well on Lowenstein-Jensen media but not on MacConkey agar; a rapid test for SD Bioline TB Ag MPT64 was performed, with negative results (Standard Diagnostics, Gyeonggi-do, Korea). Cultures performed using solid media revealed yellow-pigmented colonies. Identification by matrixassisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF; Bruker Daltonics, Leipzig, Germany) was performed identifying the colonies as Mycobacterium [7] a Clarithromycin 500 mg twice a day and levofloxacin 500 mg twice a day were initiated 2 months after symptoms were first noted and 1 month after the patient was first seen in the emergency room. Clinical response was discernible within 2 weeks; pain began to resolve, and erythema and swelling decreased. By 6 weeks of therapy, the patient was asymptomatic, with minimal swelling and fading erythema. b After the initial 45 days of antituberculosis therapy and the following 45 days of antimicrobial therapy of nontuberculous pulmonary infection (amikacin plus ciprofloxacin), the patient's general condition improved.
monacense. The acquired mass spectra were compared to Mycobacteria Library 2.0 reference spectra using MALDI Biotyper 3.1 software (Bruker). PCR restriction enzyme analysis (PRA)-hsp65 was performed as described elsewhere [8] . The PRA-hsp65 assay also identified the isolate as M. monacense. The sequencing of hsp65 and rpoB genes confirmed the identity of the M. monacense isolate. The analysis of the nucleotide sequences were performed with MEGA 6 6.06 and National Center for Biotechnology Information BLAST (Basic Local Alignment Search Tool; http://blast.ncbi.nlm.nih.gov/). The hsp65 and rpoB nucleotide sequences were deposited into GenBank with the following accession numbers: hsp65, KU361326l and rpoB, KU361327. Susceptibility testing was performed using the rapid growing mycobacteria plate (Sensititre RAPMYCOI; Thermo Scientific, Waltham, MA, USA), showing the following breakpoints (mg/L): trimethoprim/sulfamethoxazole 0.25/4.75, linezolid 1, ciprofloxacin 1, imipenem 4, moxifloxacin 0.25, cefepime 8, cefoxitin 64, amoxicillin/clavulanic acid 2/1, amikacin 1, ceftriaxone 4, doxycycline 0.12, minocycline 1, tigecycline 0.030, tobramycin 16 and clarithromycin 8. No interpretation of the breakpoints was performed because there are no breakpoints available for M. monancense in the international guidelines. In this case, we also performed an Etest, which obtained the same results as RAPMYCOI, which indicates that the Etest may be helpful when access to microdilution is not possible.
The patient received a short course of oral steroids pending the microbiologic and pathologic results, with partial relief of her symptoms. The patient was informed of the diagnosis of Mycobacterium monacense by phone, with the recommendation that she go to hospital for the treatment to be adjusted, but the patient did not return for a follow-up consultation.
Discussion
The first description of the species M. monacense was made in 2006 in three nonrelated respiratory samples and one tissue biopsy sample from a posttraumatic wound infection [2] . To our knowledge, there are five additional reports on the isolation of M. monacense in clinical samples after the initial description (Table 1) . In six respiratory samples [2, 4, 6, 7] , the clinical significance of the isolation could not be proved in three. In the two soft tissue infections, the clinical relevance was clarified in one of the cases [5] .
Rapidly growing nontuberculous mycobacteria are an increasingly recognized cause of skin and soft tissue infections, with M. abscessus, M. fortuitum and M. chelonae being the most common species involved. According to the clinical history, the nodular lesions preceded the topical steroid injections on the legs, suggesting that M. monacense caused a secondary infection of the lesions, with the port of entry being the steroid injections. Because the patient was lost to follow-up we were unable to perform further evaluation.
Nowadays, MALDI-TOF is a good tool for the diagnosis of rapid growing mycobacteria as long as the bacteria is included in the software database. Further, PCR restriction enzyme analysis has limitations, as sometimes it is not possible to distinguish among species. For these reasons, we consider that sequencing is a must when identifying rapidly growing mycobacteria [9] . In this study, the three techniques we used verified the first identification, confirming the results, but this is not always the case for noncommon rapidly growing mycobacteria or those not previously described.
